Dynavax Technologies
Commercial-stage biopharmaceutical company developing and commercializing vaccines and immunotherapies, with an approved hepatitis B vaccine and pipeline targeting infectious diseases and oncology.
Notes
Dynavax Technologies is a commercial-stage biopharmaceutical company headquartered in Emeryville, California. The company is focused on developing and commercializing novel vaccines and immunotherapies based on its proprietary CpG 1018 adjuvant technology.
Dynavax's lead product, HEPLISAV-B, is an FDA-approved hepatitis B vaccine that uses the company's CpG 1018 adjuvant to provide enhanced immune response with fewer doses. The CpG 1018 adjuvant was also licensed for use in COVID-19 vaccines during the pandemic.
Dynavax is publicly traded on NASDAQ under the ticker DVAX.
Team
- Ryan Spencer - Chief Executive Officer
- Kelly MacDonald - Chief Financial Officer
- Robert Janssen, M.D. - Chief Medical Officer
Additional Research Findings
- Founded in 1996
- Publicly traded: NASDAQ (DVAX)
- Headquarters: Emeryville, California
- Lead product: HEPLISAV-B (hepatitis B vaccine) - FDA approved 2017
- Proprietary CpG 1018 adjuvant technology
- CpG 1018 licensed for COVID-19 vaccines globally
- Commercial partnerships for adjuvant supply
- Focus on infectious diseases and immuno-oncology
- Manufacturing facility in Düsseldorf, Germany